Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. The Company is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+6.67%	-11.11%

08-12	Revive Therapeutics Reports Positive Results from Drdc Bucillamine Nerve-Agent Research Study	CI
06-25	Revive Therapeutics Ltd. announced that it expects to receive CAD 1 million in funding	CI

Market Cap	13.07M 9.23M 8.11M 7.67M 6.96M 886M 13.15M 91.87M 35.48M 452M 34.64M 33.89M 1.45B	P/E 2024	-0.68x	P/E 2025	-0.76x
Enterprise Value	13.12M 9.26M 8.15M 7.7M 6.99M 889M 13.2M 92.24M 35.62M 454M 34.78M 34.02M 1.46B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	94.62%	Yield 2024 *	-	Yield 2025	-

08-12	Revive Therapeutics Reports Positive Results from Drdc Bucillamine Nerve-Agent Research Study	CI
06-25	Revive Therapeutics Ltd. announced that it expects to receive CAD 1 million in funding	CI
06-02	Revive Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-20	Revive Therapeutics Ltd. Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures	CI
02-28	Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
12-15	Revive Therapeutics Ltd. Provides Update of Key Nerve Agent Countermeasure Study	CI
12-15	Revive Therapeutics provides update of key nerve agent countermeasure study	RE
11-28	Revive Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2025	CI
11-21	Revive Therapeutics provides update of key nerve agent countermeasure study	RE
11-21	Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study	MT
25-10-28	Revive Therapeutics Ltd. Reports Earnings Results for the Full Year Ended June 30, 2025	CI
25-10-27	Revive Therapeutics Ltd. Auditor Raises 'Going Concern' Doubt	CI
25-09-19	Revive Therapeutics announces closing of second tranche of private placement	RE

09-15	Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases	AQ
08-19	Revive Therapeutics Announces Proposed Shares for Debt Settlement	AQ
08-19	Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio	AQ
08-14	Revive Therapeutics Reports Grant of Options	AQ
08-12	Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study	AQ

Revive Therapeutics Ltd Stock Toronto S.E.

Stocks

RVV

CA7615161030

Biotechnology & Medical Research

Valuation: Revive Therapeutics Ltd

Latest news: Revive Therapeutics Ltd

Press Releases: Revive Therapeutics Ltd

News in other languages: Revive Therapeutics Ltd

Managers and Directors: Revive Therapeutics Ltd

Bio Therapeutic Drugs

Financials

Company Profile

23-01-13	Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde
23-01-13	Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde
23-01-12	Revive Therapeutics Ltd. schließt Emission in Höhe von 4,3 Mio. Dollar ab
23-01-12	Revive Therapeutics Ltd. schließt Emission in Höhe von 4,3 Mio. Dollar ab

Manager	Title	Age	Since
Michael Frank CEO	Chief Executive Officer	-	2019-12-17
Carmelo Marrelli DFI	Director of Finance/CFO	55	-

Director	Title	Age	Since
William Jackson BRD	Director/Board Member	68	2013-12-31
Michael Frank CHM	Chairman	-	2019-12-17
Joshua Herman BRD	Director/Board Member	-	2019-12-17

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REVIVE THERAPEUTICS LTD	-.--%	+6.67%	-	-	6.16M
WUXI APPTEC CO., LTD.	-0.37%	+1.12%	+57.21%	+84.56%	72.26B
ARGENX SE	-0.07%	-3.08%	+37.74%	+84.21%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+0.75%	+6.06%	+36.71%	+19.87%	27.73B
INSMED INCORPORATED	-0.14%	-2.75%	-16.93%	+356.79%	25.73B
BIONTECH SE	+0.57%	+1.10%	+1.00%	-2.89%	24.75B
GENMAB A/S	+1.10%	+1.86%	+25.07%	-8.51%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+323.16%	15.06B
EXELIXIS, INC.	+0.36%	+2.01%	+43.87%	+160.70%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.53%	-1.39%	-6.38%	+469.36%	14.23B
Average	-0.20%	-0.13%	+36.50%	+165.25%	30.57B
Weighted average by Cap.	-0.12%	-1.05%	+37.58%	+125.49%

	2024	2025
Net sales	-	-
Net income	-5.62M -3.97M -3.49M -3.3M -2.99M -381M -5.65M -39.49M -15.25M -194M -14.89M -14.57M -624M	-11.01M -7.77M -6.84M -6.46M -5.86M -746M -11.08M -77.4M -29.89M -381M -29.18M -28.55M -1.22B
Net Debt	-748K -528K -464K -439K -398K -50.67M -752K -5.26M -2.03M -25.86M -1.98M -1.94M -83.09M	52.31K 36.92K 32.47K 30.71K 27.85K 3.54M 52.61K 368K 142K 1.81M 139K 136K 5.81M